Kaerus Bioscience

News

Servier has pushed its emerging neurology pipeline into the clinical trials stage by licensing a drug for Fragile X syndrome from the UK's Kaerus.

News

Five scientific teams will receive up to £20m each in a new round of funding under the UK and US Cancer Grand Challenges initiative.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.